CD19 – Medxy AI

$Off-the-Shelf, Non-Gene-Edited Allogeneic CD19 CAR-T Cells Show Early Feasibility in Relapsed or Refractory B-ALL$

Off-the-Shelf, Non-Gene-Edited Allogeneic CD19 CAR-T Cells Show Early Feasibility in Relapsed or Refractory B-ALL

By MedXY 06/06/2026

A phase 1 study suggests non-gene-edited allogeneic CD19 CAR-T therapy can induce remissions in relapsed or refractory B-ALL without observed GVHD, though durability remains limited and larger trials are needed.

Hematology-Oncology news

Cellular and Molecular Mechanisms of Relapse After CD19/CD22 Dual-Target CAR T-Cell Therapy in B-Cell Acute Lymphoblastic Leukemia

By MedXY 06/02/2026

A study of 91 B-ALL patients found that relapse after CD19/CD22 dual-target CAR T-cell therapy is mainly driven by CAR T-cell functional failure and antigen loss, with PAX5 mutations linked to early immune escape.

Neurology news

FDA Approves Inebilizumab (Uplizna) for Antibody-Positive Generalized Myasthenia Gravis: Interpreting the MINT Trial and Clinical Implications

By MedXY 12/15/2025

The FDA has approved inebilizumab-cdon (Uplizna) for adults with AChR- or MuSK-antibody positive generalized myasthenia gravis based on the phase 3 MINT trial showing a 1.9-point MG‑ADL improvement at 26 weeks versus placebo and sustained benefit in AChR+ patients through 52 weeks.

Hematology-Oncology news

AZD0120 (GC012F) Dual-Target BCMA/CD19 CAR‑T Shows Promising Early Activity and Favorable Safety in RRMM: Interpreting ASH 2025 Ib Data

By MedXY 12/08/2025

Early Ib results from AstraZeneca’s AZD0120 (GC012F), a FasTCAR-derived BCMA/CD19 dual-target CAR‑T, reported 100% ORR in evaluable RRMM patients with low-grade CRS and no ICANS. Findings are encouraging but limited by small numbers and short follow-up.

$Dual CD19/BCMA CAR‑T Cells Produce Deep, Durable Remissions in Refractory SLE — Phase 1 Data Show Promise for a Curative Approach$

Hematology-Oncology news Rheumatology

Dual CD19/BCMA CAR‑T Cells Produce Deep, Durable Remissions in Refractory SLE — Phase 1 Data Show Promise for a Curative Approach

By MedXY 11/12/2025

In a phase 1 trial, co‑infused autologous CD19- and BCMA-targeting CAR‑T cells produced 80% LLDAS/DORIS remission at 12 weeks in 15 refractory SLE patients, with manageable toxicity and evidence of eradication of autoreactive B‑cell and plasma‑cell clones.

$Innovative Allogeneic CD19-Targeting T Cells Show Promise in Refractory Systemic Lupus Erythematosus with Lupus Nephritis$

Allergy & Immunology Clinical Updates Rheumatology Specialties

Innovative Allogeneic CD19-Targeting T Cells Show Promise in Refractory Systemic Lupus Erythematosus with Lupus Nephritis

By MedXY 09/04/2025

A phase 1 trial demonstrates that the allogeneic CD19-targeting T cell therapy YTS109 is safe and induces clinical remission, immune resetting, and renal tissue restoration in patients with refractory systemic lupus erythematosus complicated by lupus nephritis.